Arca
Skip to content
Tools
Tools

Glutamate receptor ionotropic kainate

Complex group in Homo sapiens that 3 drugs act on.

  • Drugs that act on it: 3
  • Approved: 1
  • In phases 1 to 3: 2
  • Sponsors: 3
  • Genes: 5

Who is on it, and how far along

Every drug ChEMBL records acting on GRIK1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 3

Approved1

  • Topiramate

Phase 30

    Phase 22

    • Selurampanel
    • Tezampanel anhydrous

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Glutamate receptor ionotropic kainate antagonist.
      TopiramateApprovedJohnson & JohnsonSmall moleculeAntagonist31
      SelurampanelPhase 2Novartis PharmaceuticalsSmall moleculeAntagonist0
      Tezampanel anhydrousPhase 2TorreyPines TherapeuticsSmall moleculeAntagonist0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
      Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1sTopiramatePhase 4Not yet recruitingJing LuoSep 21, 2026
      Discontinuing Psychotropic Medication Before Psychotherapy for PTSDTopiramate—Not yet recruitingAcademic Centre for Dentistry in AmsterdamSep 3, 2026
      Obesity Treatment With Phentermine-Topiramate ER in AYA Surviving Leukemia and LymphomaTopiramatePhase 2Not yet recruitingSt. Jude Children's Research HospitalAug 27, 2026
      Pragmatic Trial to Study the Cost-Effectiveness of MyPhenome-RX Test to Guide Anti-Obesity PharmacotherapyTopiramateNot applicableNot yet recruitingPhenomix SciencesJul 27, 2026
      Idiopathic Intracranial Hypertension: Prognostic Factors and Multidisciplinary ManagementTopiramateNot applicableActive, not recruitingSohag UniversityJul 16, 2026
      Comparing Migraine Preventive Therapies vs. Anti-CGRP Therapies for Tinnitus in Patients With Migraine (COMPACT-PM)TopiramatePhase 4Not yet recruitingStanford UniversityJun 17, 2026
      Neurophysiological Effects of Medication Tapering During Treatment With Spinal Cord StimulationTopiramate—RecruitingBrai²nFeb 17, 2026
      Combining Latency Reversing Agents to Address the HIV ReservoirTopiramatePhase 1 / Phase 2Not yet recruitingErasmus Medical CenterFeb 3, 2026

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2109241, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.